Zheng X, Xu Z, Ji Q, Ge M, et al. A randomized, phase 3 study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer. Clin Cancer Res 2021 Jul 29. pii: 1078-0432.CCR-21-0761.
PMID: 34326132